Johnson & Johnson (JNJ)
After hours:
| Previous close | 179.52 |
| Open | 178.83 |
| Bid | 177.75 x 800 |
| Ask | 177.76 x 800 |
| Day's range | 174.61 - 179.12 |
| 52-week range | 155.72 - 186.69 |
| Volume | |
| Avg. volume | 7,668,911 |
| Market cap | 468.889B |
| Beta (5Y monthly) | 0.66 |
| PE ratio (TTM) | 24.01 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 4.52 (2.52%) |
| Ex-dividend date | 23 May 2022 |
| 1y target est | N/A |
- PR Newswire
Johnson & Johnson Opens First Satellite Center for Global Health Discovery in Asia Pacific at Duke-NUS to Advance Dengue Research
Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of the new J&J Satellite Center for Global Health Discovery (Satellite Center) at Singapore's Duke-NUS Medical School, jointly established by Duke University and the National University of Singapore (NUS) as a graduate-entry medical school and research powerhouse. As the first of the J&J Centers for Global Health Discovery (J&J Centers) in the Asia-Pacific region, the Satellite Center at Duke-NUS aims to help drive new soluti
- PR Newswire
Johnson & Johnson Releases 2021 Health for Humanity Report Highlighting Performance on ESG Priorities and Progress Against Public Commitments
Johnson & Johnson (NYSE: JNJ) today published its 2021 Health for Humanity Report, which shares progress against its purpose-driven Health for Humanity 2025 Goals and serves as its annual disclosure on environmental, social and governance (ESG) performance. In year one, we have exceeded one Health for Humanity 2025 Goal and are on track to deliver against the remaining 20 goals.
- PR Newswire
Johnson & Johnson Appoints Thibaut Mongon as CEO Designate of Planned New Consumer Health Company
Johnson & Johnson (the "Company") (NYSE: JNJ) today announced the appointment of Thibaut Mongon as Chief Executive Officer Designate and Paul Ruh as Chief Financial Officer Designate of the future, listed New Consumer Health Company.
